Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.74 and traded as high as $2.34. Caladrius Biosciences shares last traded at $2.17, with a volume of 6 shares trading hands.
A number of research analysts have recently weighed in on CLBS shares. Zacks Investment Research cut Caladrius Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. ValuEngine raised Caladrius Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.63.
The firm has a 50 day moving average of $2.44 and a 200-day moving average of $2.74. The company has a market cap of $22.88 million, a P/E ratio of -1.34 and a beta of 1.48.
Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Equities research analysts expect that Caladrius Biosciences Inc will post -1.54 EPS for the current fiscal year.
An institutional investor recently raised its position in Caladrius Biosciences stock. Vanguard Group Inc. boosted its holdings in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 7.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 207,973 shares of the biotechnology company’s stock after purchasing an additional 14,740 shares during the quarter. Vanguard Group Inc. owned about 2.00% of Caladrius Biosciences worth $474,000 at the end of the most recent quarter. 8.03% of the stock is currently owned by institutional investors.
Caladrius Biosciences Company Profile (NASDAQ:CLBS)
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.